Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing multi-node inhibitors of the PI3K/AKT/mTOR pathway for the treatment of cancer. The company’s lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to simultaneously inhibit PI3K-alpha, mTORC1, and mTORC2. PIKTOR is currently in Phase 2 clinical trials for advanced endometrial cancer and is planned for Phase 1b trials in HR+/HER2- advanced breast cancer. The company also maintains preclinical programs, including NEAAR and IEM, and intends to explore additional indications such as ovarian and lung cancer. Faeth Therapeutics was co-founded in 2019 and completed a reverse merger with Sensei Biotherapeutics in February 2026, which brought PIKTOR into the combined entity’s pipeline.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage faeththerapeutics.com
Sector Healthcare IR page investors.faeththerapeutics.com
Tags
oncology, multi-node inhibition, pi3k/akt/mtor pathway, endometrial cancer, breast cancer, oral therapeutics, clinical-stage, tumor metabolism, signaling pathways, PIKTOR, serabelisib, sapanisertib, NEAAR, IEM, Faeth HoldCo, Faeth Subsidiary, Sensei Biotherapeutics
Press page —

Metrics

Valuation  
Market cap $ 768.551M
Market cap (USD) $ 768.551M
P/E —
PEG —
P/BV 4.77
P/S —
P/OCF -17.76
P/FCF -17.76
Dividend yield —
Turnover / mcap —
Returns  
ROE -74.0%
ROI -212.5%
ROIC -168.4%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score -55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 22.902M 45.361M 74.374M 118.375M 153.225M 21.428M
Net profit -21.085M -30.157M -34.101M -48.588M -36.794M -20.1M
Free cash flow -20.469M -24.816M -32.203M -39.347M -32.285M -18.911M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 10.67 — — — — —
P/FCF -0.66 — — — — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) 567,000 — — — — —
Lease liabilities (USD) 118,000 2.35M 8.03M 6.21M 3.85M 1.51M
Cash and deposits (USD) 16.6M 7.16M 17.8M 13M 9.99M 8.67M
Right-of-use assets (USD) — — 5.36M 4.33M 2.8M 1.29M
Net debt (borrowings + leases - cash) (USD) -16M — — — — —
Cash flow detail
Operating cash flow (USD) -17.7M -30.3M -39M -32M -24.7M -20.5M
Purchases of property, plant and equipment (USD) -1.21M -2.03M -321,000 -180,000 -146,000 -16,000
Change in payables (cash effect) (USD) 335,000 -1.43M 2.02M -2.33M -445,000 233,000
Share buybacks (cash effect) (USD) — — — -10.4M — —
Share-based compensation (USD) 1.49M 5.66M 5.81M 4.45M 3.14M 1.27M
Free cash flow (OCF - PPE - intangibles) (USD) -18.9M -32.3M -39.3M -32.2M -24.8M -20.5M
Income detail
Total comprehensive income (USD) -20.2M -37.1M -49.3M -33.3M -30M -21.1M
Comprehensive income to owners (USD) -20.2M -37.1M -49.3M -33.3M -30M -21.1M
Reported Mar 15, 2022 Mar 15, 2022 Mar 29, 2023 Feb 29, 2024 Mar 28, 2025 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Faeth Therapeutics, Inc. — Other Events Bull 5 Bear 0 Clinical/regulatory

On November 9, 2026, Faeth Therapeutics, Inc. (the “Company”) made available a presentation to be used to discuss, among other things, the topline clinical data from the Company’s Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

• Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83%

• Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16)

• Preliminary Kaplan-Meier estimated median progression-free survival (mPFS) of 7.4 months, with a 6-month PFS rate of 62%

• The combination of PIKTOR with paclitaxel was generally well tolerated, with a treatment-related hyperglycemia rate of 12% (2% Gr. 3) and stomatitis rate of 21% (2% Gr. 3), and a discontinuation rate of 5% due to treatment-related adverse events

• Data support advancement of PIKTOR development into a Phase 3 registrational trial

• Webcast today at 8 a.m.

• FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer

• Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026

AUSTIN, Texas—(BUSINESS WIRE)—November 3, 2026— Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones.

“Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2 PIK-201 trial and received Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer,” said Anand Parikh, Chief Executive Officer. “The PAM pathway is dysregulated in up to 50% of solid tumors, and feedback reactivation and resistance mutations may limit single-node inhibitors. We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option.

Prompts

Faeth Therapeutics, Inc. (ticker FTH), listed in United States.

Company History

Date Change Detail
Jun 18, 2026 Renamed SENSEI BIOTHERAPEUTICS, INC. → FAETH THERAPEUTICS, INC.
— Former tickers SNSE

ETFs Holding Faeth Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 4,772 $ 44.284K Nov 16, 2026